SavedAdd your journal

Journals / Akdeniz Tıp Dergisi / 2021 / Cilt: 7 - Sayı: 2

Pharmacogenetic Approaches to Depression in Old Age

İleri Yaş Depresyonunda Farmakogenetik Yaklaşımlar

Gül ÖZBEY
Ceyda ÖZKOÇ
Yunus Emre ÖZKAN
Kübra KOÇ
Pages
173–179
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review covers articles investigating the effects of genetic polymorphisms on pharmacokinetics, therapeutic response and advers drug reactions of antidepressants in late-life depression.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Late-life depression is a kind of major depressive disorder which depressive symptoms occurs after the age of 50-65 years.
📊
Key Findings & Data:Although the majority of researchs on pharmacogenetics of antidepressants have been reported for the younger adults, genetic variations that influence antidepressant treatment in late-life depression should be elucidated for identification of pharmacogenetic testing strategies.
💡
Conclusion & Impact:This review covers articles investigating the effects of genetic polymorphisms on pharmacokinetics, therapeutic response and advers drug reactions of antidepressants in late-life depression.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Antidepresan · Farmakogenetik · Yaşlılık-çağı depresyonu

Abstract

Late-life depression is a kind of major depressive disorder which depressive symptoms occurs after the age of 50-65 years. Approximately one-third of patients with late-life depression do not respond to current used antidepressants. Therefore, translation of pharmacogenetic knowledge into clinical practice in late-life depression may provide improving efficacy and reducing side effects of antidepressants. Although the majority of researchs on pharmacogenetics of antidepressants have been reported for the younger adults, genetic variations that influence antidepressant treatment in late-life depression should be elucidated for identification of pharmacogenetic testing strategies. This review covers articles investigating the effects of genetic polymorphisms on pharmacokinetics, therapeutic response and advers drug reactions of antidepressants in late-life depression.

Özet

Yaşlılık çağı depresyonu, depresif semptomların 50-65 yaştan sonra ortaya çıktığı bir majör depresif bozukluk türüdür. Yaşlılık çağı depresyonu hastalarının yaklaşık olarak üçte biri günümüzde kullanılan antidepresanlara yanıt vermemektedir. Farmakogenetik bilginin klinik pratiğe aktarılması yaşlılık çağı depresyonu hastalarında antidepresanların etkinliğinin artırılmasını ve yan etkilerinin azaltılmasını sağlayabilir. Antidepresanların farmakogenetiği ile ilgili çalışmaların birçoğu genç erişkinlerde yapıldığından, farmakogenetik test stratejilerinin belirlenmesi için yaşlılık çağı depresyonunda antidepresan tedaviyi etkileyen genetik varyasyonların aydınlatılması gerekmektedir. Bu derleme yaşlılık çağı depresyonunda genetik polimorfizmlerin antidepresanların farmakokinetiği, terapötik yanıt ve advers ilaç reaksiyonları üzerindeki etkilerini araştıran makaleleri kapsamaktadır.

🔖

Cite This Article

ÖZBEY, G., ÖZKOÇ, C., ÖZKAN, Y. E., KOÇ, K. (2022). Pharmacogenetic Approaches to Depression in Old Age. Akdeniz Tıp Dergisi, Cilt: 7 - Sayı: 2, 173–179. https://ajindex.com/articles/434219

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Sachs-Ericsson N, Moxley JH, Corsentino E, Rushing NC, Sheffler J, Selby EA, Gotlib I, Steffens DC. Melancholia in later life: late and early onset differences in presentation, course, and dementia risk. Int J Geriatr Psychiatry 2014; 29:943-51
  2. Naismith SL, Norrie LM, Mowszowski L, Hickie IB. The neurobiology of depression in later-life: clinical, neuropsychological, neuroimaging and pathophysiological features. Prog Neurobiol 2012; 98:99-143
  3. Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord 2012; 141:103-15
  4. Bigos KL, Bies RR, Pollock BG. Population pharmacokinetics in geriatric psychiatry. Am J Geriatr Psychiatry 2006; 14:993-1003
  5. Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Cao Z. Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry 2011; 19:211-21
  6. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365:2002-12
  7. Marshe VS, Islam F, Maciukiewicz M, Bousman C, Eyre HA, Lavretsky H, Mulsant BH, Reynolds CF 3rd, Lenze EJ, Müller DJ. Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. Am J Geriatr Psychiatry 2020; 28:609-29
  8. Abbott R, Chang DD, Eyre HA, Bousman CA, Merrill DA, Lavretsky H. Pharmacogenetic Decision Support Tools: A New Paradigm for Late-Life Depression? Am J Geriatr Psychiatry 2018; 26:125-33
  9. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9:442-73
  10. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138:103-41
  11. Dücker CM, Brockmöller J. Genomic Variation and Pharmacokinetics in Old Age: A Quantitative Review of Age- vs. Genotype-Related Differences. Clin Pharmacol Ther 2019; 105:625-40
  12. Ponticelli C, Sala G, Glassock RJ. Drug management in the elderly adult with chronic kidney disease: a review for the primary care physician. Mayo Cl